Nara Organics expands with new whole milk infant formula

USA – Nara Organics has introduced its latest FDA-registered and USDA-certified organic whole milk infant formula that meets both USA and European safety standards.

Developed by a team of mothers, scientists, pediatricians, and nutritionists, Nara Organics stated that the offering is positioned as a cleaner, more transparent alternative in a category dominated by a few legacy manufacturers.

The product is manufactured in Germany to meet stringent EU and USA regulations and includes key nutritional elements like naturally occurring milk fat globule membrane, European-required levels of docosahexaenoic acid, and prebiotics.

Esther Hallam, founder and CEO of Nara Organics, stated, “I created Nara because it’s the formula I wish existed for my daughter. We spent seven years developing this product with no compromises, so that parents who are still demanding better don’t have to settle.”

Additionally, the company also revealed it has completed a large-scale, double-blinded clinical trial to demonstrate the formula’s safety and efficacy and has received the Clean Label Purity Award for its testing for contaminants such as lead and arsenic.

The company raised US$32 million from venture firms and individual investors, including the elite tennis pro, Serena Williams, and Erin and Sara Foster, actors, producers, and podcasters who serve as brand advisors. Hallam says she built a community of over one million parents through the Nara Baby + Mom Tracker app.

As part of its launch, the company is donating over 1,400 cans of formula to Good+ Foundation, supporting consistent infant nutrition for under-resourced families. This initiative will scale alongside Nara’s growth.

FDA unveils strategy to strengthen USA infant formula

The new product comes after the USA Food and Drug Administration introduced a long-term strategy to strengthen the resilience of the infant formula market, aiming to prevent a repeat of the 2022 recall and subsequent shortages. 

Reported by the agency, the strategy focuses on diversification, risk management, and improved supply chain oversight to address vulnerabilities in this highly concentrated market, where the number of major manufacturers has decreased from four to three since 2022.

According to the FDA, a key component of the strategy includes enhanced surveillance and safety inspections, ensuring that all infant formula manufacturers undergo annual sampling and regulatory evaluations. 

The agency has also committed to collecting microbiological and nutritional samples from foreign manufacturers each year and has intensified efforts to combat Cronobacter contamination through industry discussions and scientific data analysis.

Subscribe to receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world. SUBSCRIBE HERE